DONALD HOLBROOKS: Open Payments
NPI 1346872512 · CLEMSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 42 payments from 12 companies in 2025. Trend: 2023 $1,042 · 2024 $638 · 2025 $686
Food & beverage: $686
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $286 |
| Celgene Corporation | 4 | $82 |
| Neurocrine BioSciences, Inc. | 4 | $79 |
| Neurelis, Inc. | 3 | $58 |
| TG Therapeutics, Inc. | 2 | $42 |
| Alexion Pharmaceuticals, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| PFIZER INC. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $17 |
Products named: UBRELVY, ZEPOSIA, INGREZZA, VRAYLAR, VALTOCO, QULIPTA, BRIUMVI, ULTOMIRIS.
Industry payments across SC — which companies pay providers there.
